Tigecycline

Glycylcycline antibiotic (tetracycline derivative), broad-spectrum antibiotic

• Binding to the 30S subunit of the bacterial ribosomes. This inhibits the translation of bacterial protein synthesis by preventing the attachment of aminoacyl-tRNA molecules to the ribosomal acceptor site (A-site). This prevents the incorporation of amino acid residues into growing peptide chains.
• Glycylcyclins bypass the two main resistance mechanisms of bacteria (efflux pumps and ribosomal protection mechanisms). Efflux pumps cause the antibiotic to be pumped out of the bacteria quickly, which considerably reduces the effectiveness of the antibiotic. Ribosomal protective mechanisms prevent antibiotics from interfering with the protein synthesis of the bacteria.

• Remember! Tigecycline is sensitive to the chromosomal multidrug efflux pumps of Proteae (Proteus spp., in particular P. mirabilis, P. vulgaris and P. myxofaciens as well as Morganella spp., in particular M. morganii and also Providencia spp., in particular P. rettgeri, P. alcalifaciens and P. stuartii) and Pseudomonas aeruginosa (MexXYOprM efflux system). There are 2 gaps in efficacy here.

Particularly broad spectrum of activity against gram-positive and gram-negative, aerobic and anaerobic as well as atypical pathogens and multi-resistant germs. Effective against MRSA, ORSA, vancomycin-resistant enterococci, tetracycline-resistant pathogens, Acinetobacter spp.

Please note! Tigecycline is not effective against Pseudomonas aeruginosa.

Initial 100 mg i.v. followed by 50 mg i.v. every 12 hours over a period of 5-14 days.